Skip to main content
    X

    Xeris Pharmaceuticals Inc (XERS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.80
    +0.10 (+0.60%)

    Market Cap: $3.05B

    Last updated: Nov 17, 2026 at 4:41 PM ET

    Xeris Pharmaceuticals Inc (XERS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Xeris Pharmaceuticals (XERS) has a market cap of $3.05B and an enterprise value of $3.11B. Its share count is up 10.57% from a year earlier. Revenue grew 38.37% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 1.92% above the market cap, as debt exceeds cash.

    Market Cap$3.05B
    Enterprise Value$3.11B
    Latest price (Nov 17, 2026)$16.80

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.70% in the quarter ended Sep 30, 2026 and grew 10.20% a year over 2 years.

    Shares Outstanding180.94M
    Shares Change (YoY)+10.57%
    Shares Change (QoQ)+4.70%
    Share Count Growth (2Y CAGR)+10.20%

    Valuation Ratios

    Sales and book value multiples are 8.3x and 62.3x.

    P/E Ratio140.0x
    P/S Ratio8.3x
    Forward P/S7.6x
    P/B Ratio62.3x
    P/OCF Ratio41.4x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 49.0x EBITDA.

    EV / Sales8.4x
    EV / EBITDA49.0x
    EV / EBIT66.5x

    Price Statistics

    The stock is up 133.98% over 52 weeks and trades 56.57% above its 50-day average.

    Beta (1Y)0.12
    52-Week Change+133.98%
    1-Month Change+53.42%
    3-Month Change+91.34%
    6-Month Change+183.78%
    5-Year Change+475.81%
    Total Return (1Y)+133.98%
    Total Return (3Y CAGR)+111.69%
    Total Return (5Y CAGR)+47.74%
    Return vs SPY (1Y)+125.73%
    Max Drawdown (1Y)-34.93%
    Max Drawdown (3Y)-47.20%
    Sharpe Ratio (1Y)1.57
    Correlation with SPY (1Y)0.03
    50-Day Average$10.73
    200-Day Average$7.92
    52-Week Range$5.25 to $16.98
    RSI (14 Days)85.8
    Average Volume (20 Days)3.37M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.15x current liabilities, and total debt is 3.89x shareholder equity.

    Current Ratio2.15x
    Quick Ratio1.58x
    Debt / Equity3.89x
    Debt / EBITDA3.00x
    Interest Coverage0.80x

    Returns and Efficiency

    Return on invested capital is 15.50% over the last 12 months, against a 5-year average of -14.88%.

    Return on Equity (ROE)-13.32%
    Return on Assets (ROA)-1.53%
    Return on Invested Capital (ROIC)15.50%
    Return on Capital Employed (ROCE)16.20%
    ROA (5Y Average)-20.79%
    ROIC (5Y Average)-14.88%
    Asset Turnover0.93x
    Inventory Turnover0.59x
    Receivables Turnover5.81x
    Cash Conversion Cycle615 days

    Scores

    XERS has an Altman Z-Score of 4.27, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score4.27
    Altman Z ZoneSafe
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue was $368.26M over the last 12 months.

    Revenue$368.26M
    Revenue Growth (YoY)+38.37%
    Gross Profit$321.80M
    Operating Income$46.78M
    Pretax Income-$6.50M
    Net Income-$6.50M
    EBITDA$63.18M
    EBIT$46.78M
    Reported EPS (TTM)$0.12

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 11.53% of the $423.22M in total assets.

    Cash and Equivalents$131.08M
    Total Debt$189.71M
    Net Debt$58.63M
    Net Debt Per Share$0.32
    Working Capital$154.79M
    Shareholder Equity$48.78M
    Book Value Per Share$0.27
    Tangible Book Value-$54.02M
    Total Assets$423.22M
    Total Liabilities$374.44M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$73.65M
    FCF Per Share$0.40
    Depreciation and Amortization$16.40M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 12.70%, against a 5-year average of -68.29%.

    Gross Margin87.38%
    Operating Margin12.70%
    Pretax Margin-1.76%
    Net Margin-1.76%
    EBITDA Margin17.16%
    EBIT Margin12.70%
    Gross Margin (5Y Average)80.48%
    Operating Margin (5Y Average)-68.29%
    Net Margin (5Y Average)-79.63%

    Growth

    Revenue grew 38.33% a year over 3 years.

    Revenue Growth (3Y CAGR)+38.33%
    Revenue Growth (5Y CAGR)+70.67%

    Revenue and profit by year

    Dividends and Yields

    XERS does not pay a dividend.

    Earnings Yield0.71%
    Buyback Yield-0.32%
    Shareholder Yield-0.32%

    Peer Position

    Against 11 similar companies, XERS has the highest P/E.

    P/E Ratio140.0x vs 10.8x median
    P/S Ratio8.3x vs 2.0x median
    ROIC15.50% vs 7.08% median
    Revenue Growth (Trailing 4 Quarters, YoY)+38.37% vs +9.85% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 34.33% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+34.33%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About XERS

    What is XERS's market cap?

    Xeris Pharmaceuticals has a market cap of $3.05B. Its enterprise value, which adds debt and subtracts cash, is $3.11B.

    What is XERS's P/E ratio?

    Xeris Pharmaceuticals has a trailing P/E ratio of 140.0x.

    How many shares of XERS are outstanding?

    Xeris Pharmaceuticals has 180.94M shares outstanding. The count is up 10.57% from a year earlier.

    Does XERS pay a dividend?

    No. Xeris Pharmaceuticals does not pay a dividend.

    How much debt does XERS have?

    Xeris Pharmaceuticals has $189.71M of total debt and $131.08M of cash and equivalents, a net debt position of $58.63M.